Clinicopathologic and molecular disease prognostication for papillary thyroid cancer

Paolo Miccoli, Mario Miccoli, Alessandro Antonelli, Michele N. Minuto

Research output: Contribution to journalArticle


Despite its increasing incidence over the last 30 years, the mortality rate of papillary thyroid cancer (PTC) has decreased significantly. Nevertheless, a minority of patients still present with an aggressive form of PTC that can lead to death, even after a prolonged period of survival. Many classifications exist that allow one to stratify the clinical risk of recurrence and death in patients with PTC; however, the parameters upon which they are established are pathological and molecular and, therefore, are revealed only after surgery. The preoperative identification of these aggressive variants of PTC would allow one to schedule a more aggressive operation (e.g., total thyroidectomy together with central and/or mono- or bi-lateral node dissections) in patients with high-risk PTC. This article reviews the parameters used most commonly to differentiate low-risk PTCs from their more aggressive variants and describes some of the newest molecular therapies for this latter group of tumors.

Original languageEnglish
Pages (from-to)1261-1275
Number of pages15
JournalExpert Review of Anticancer Therapy
Issue number9
Publication statusPublished - Sep 2009


  • Papillary thyroid cancer
  • Postoperative therapy
  • Prognostic factors
  • Surgery

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Fingerprint Dive into the research topics of 'Clinicopathologic and molecular disease prognostication for papillary thyroid cancer'. Together they form a unique fingerprint.

  • Cite this